Jennifer L Taylor-Cousar, Mscs

List of Publications by Year
in descending order

63 papers	4,836 citations	304701 22 h-index	118840 62 g-index
63 all docs	63 docs citations	63 times ranked	2882 citing authors

#	Article	IF	Citations
1	Cardiovascular complications in cystic fibrosis: A review of the literature. Journal of Cystic Fibrosis, 2022, 21, 18-25.	0.7	25
2	Pregnancy in cystic fibrosis: Review of the literature and expert recommendations. Journal of Cystic Fibrosis, 2022, 21, 387-395.	0.7	28
3	Impact of Cystic Fibrosis Transmembrane Conductance Regulator Therapy on Chronic Rhinosinusitis and Health Status: Deep Learning CT Analysis and Patient-reported Outcomes. Annals of the American Thoracic Society, 2022, 19, 12-19.	3.2	37
4	Familyâ€building and parenting considerations for people with cystic fibrosis. Pediatric Pulmonology, 2022, 57, .	2.0	9
5	Olfactory dysfunction in cystic fibrosis: Impact of CFTR modulator therapy. Journal of Cystic Fibrosis, 2022, 21, e141-e147.	0.7	15
6	Optimizing sexual and reproductive health across the lifespan in people with cystic fibrosis. Pediatric Pulmonology, 2022, 57, .	2.0	8
7	Engaging Stakeholders in the Development of a Reproductive Goals Decision AID for Women with Cystic Fibrosis. Journal of Patient Experience, 2022, 9, 237437352210775.	0.9	4
8	Olfactory dysfunction in people with cystic fibrosis with at least one copy of F508del. International Forum of Allergy and Rhinology, 2022, 12, 963-966.	2.8	5
9	Parenthood impacts short-term health outcomes in people with cystic fibrosis. Journal of Cystic Fibrosis, 2022, , .	0.7	8
10	A survey: Understanding the health and perspectives of people with CF not benefiting from CFTR modulators. Pediatric Pulmonology, 2022, 57, 1253-1261.	2.0	13
11	DNA sequencing analysis of cystic fibrosis transmembrane conductance regulator gene identifies cystic fibrosisâ€associated variants in the Severe Asthma Research Program. Pediatric Pulmonology, 2022, 57, 1782-1788.	2.0	3
12	Blood mRNA biomarkers distinguish variable systemic and sputum inflammation at treatment initiation of inhaled antibiotics in cystic fibrosis: A prospective non-randomized trial. PLoS ONE, 2022, 17, e0267592.	2.5	1
13	Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: the MAYFLOWERS observational clinical trial study design. BMJ Open Respiratory Research, 2022, 9, e001289.	3.0	20
14	Management of pregnancy in cystic fibrosis. Breathe, 2022, 18, 220005.	1.3	7
15	Machine learning evaluates improvement in sinus computed tomography opacification with CFTR modulator therapy. International Forum of Allergy and Rhinology, 2021, 11, 953-954.	2.8	6
16	Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 381-385.	5.6	116
17	Development of elexacaftor â€“ tezacaftor â€“ ivacaftor: Highly effective CFTR modulation for the majority of people with Cystic Fibrosis. Expert Review of Respiratory Medicine, 2021, 15, 723-735.	2.5	23
18	Restarting Respiratory Clinical Research in the Era of the Coronavirus Disease 2019 Pandemic. Chest, 2021, 159, 1173-1181.	0.8	2

#	Article	IF	Citations
19	Concerns regarding the safety of azithromycin in pregnancy - relevance for women with cystic fibrosis. Journal of Cystic Fibrosis, 2021, 20, 395-396.	0.7	9
20	Fertility, Pregnancy and Lactation Considerations for Women with CF in the CFTR Modulator Era. Journal of Personalized Medicine, 2021, 11, 418.	2.5	22
21	Challenges in the use of highly effective modulator treatment for cystic fibrosis. Journal of Cystic Fibrosis, 2021, 20, 381-387.	0.7	19
22	Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation. Journal of Cystic Fibrosis, 2021, 20, 402-406.	0.7	52
23	USE OF COMPUTED TOMOGRAPHY (CT) TO DETERMINE THE SENSITIVITY OF CLINICAL SIGNS AS A DIAGNOSTIC TOOL FOR RESPIRATORY DISEASE IN BORNEAN ORANGUTANS (PONGO PYGMAEUS). Journal of Zoo and Wildlife Medicine, 2021, 52, 470-478.	0.6	3
24	Combination CFTR modulator therapy in children and adults with cystic fibrosis. Lancet Respiratory Medicine,the, 2021, 9, 677-679.	10.7	4
25	Fertility and Pregnancy in Cystic Fibrosis. Chest, 2021, 160, 2051-2060.	0.8	26
26	Triple Therapy for Cystic Fibrosis Phe508delâ€“Gating and â€“Residual Function Genotypes. New England Journal of Medicine, 2021, 385, 815-825.	27.0	140
27	Riociguat for the treatment of Phe508del homozygous adults with cystic fibrosis. Journal of Cystic Fibrosis, 2021, 20, 1018-1025.	0.7	5
28	Triple combination cystic fibrosis transmembrane conductance regulator modulator therapy in the real world â€“ opportunities and challenges. Current Opinion in Pulmonary Medicine, 2021, 27, 554-566.	2.6	17
29	Challenges Faced by Women with Cystic Fibrosis. Clinics in Chest Medicine, 2021, 42, 517-530.	2.1	9
30	Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis. Journal of Cystic Fibrosis, 2021, 20, 1026-1034.	0.7	9
31	EVALUATING THE EFFICACY OF HUMAN BRONCHIECTASISBASED ANTIBIOTIC THERAPY IN THE TREATMENT OF ORANGUTAN RESPIRATORY DISEASE SYNDROME. Journal of Zoo and Wildlife Medicine, 2021, 52, 1205-1216.	0.6	1
32	Letter to the editor: Challenges and opportunities in the development of future CFTR modulator options for people with CF. Journal of Cystic Fibrosis, 2020, 19, e1-e2.	0.7	2
33	CFTR Modulators: Impact on Fertility, Pregnancy, and Lactation in Women with Cystic Fibrosis. Journal of Clinical Medicine, 2020, 9, 2706.	2.4	39
34	Transparency and diversity in cystic fibrosis research â€“ Authors' reply. Lancet, The, 2020, 396, 602.	13.7	0
35	Outcomes of pregnancy in women with cystic fibrosis (CF) taking CFTR modulators â€“ an international survey. Journal of Cystic Fibrosis, 2020, 19, 521-526.	0.7	57
36	â€˜Go for it, dream big, work hard and persistâ€™: A message to the next generation of CF leaders in recognition of International Women's Day 2020. Journal of Cystic Fibrosis, 2020, 19, 184-193.	0.7	3

#	Article	IF	Citations
37	Contraceptive use among women with cystic fibrosis: A pilot study linking reproductive health questions to the Cystic Fibrosis Foundation National Patient Registry. Contraception, 2020, 101, 420-426.	1.5	22
38	Potentially lethal cystic fibrosis gene variant in the orangutan. American Journal of Primatology, 2020, 83, e23097.	1.7	3
39	Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease. European Respiratory Review, 2020, 29, 190112.	7.1	69
40	Men's health in the modern era of cystic fibrosis. Journal of Cystic Fibrosis, 2020, 20, e121-e123.	0.7	6
41	Elexacaftorâ€“Tezacaftorâ€“Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. New England Journal of Medicine, 2019, 381, 1809-1819.	27.0	1,231
42	Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet, The, 2019, 394, 1940-1948.	13.7	804
43	Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles. ERJ Open Research, 2019, 5, 00082-2019.	2.6	72
44	Prospective multicenter randomized patient recruitment and sample collection to enable future measurements of sputum biomarkers of inflammation in an observational study of cystic fibrosis. BMC Medical Research Methodology, 2019, 19, 88.	3.1	8
45	The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy. Therapeutic Advances in Respiratory Disease, 2019, 13, 175346661984442.	2.6	19
46	Oral Azithromycin Use and the Recovery of Lung Function from Pulmonary Exacerbations Treated with Intravenous Tobramycin or Colistimethate in Adults with Cystic Fibrosis. Annals of the American Thoracic Society, 2019, 16, 853-860.	3.2	12
47	Positive clinical response to ivacaftor treatment in an individual with the CFTR genotype F508del/V456A. Journal of Cystic Fibrosis, 2019, 18, e9-e10.	0.7	2
48	Let's talk about sex: Behaviors, experience and health care utilization in young women with CF. Journal of Cystic Fibrosis, 2018, 17, 5-6.	0.7	3
49	Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR. Journal of Cystic Fibrosis, 2018, 17, 228-235.	0.7	62
50	Corticosteroid use and increased CXCR2 levels on leukocytes are associated with lumacaftor/ivacaftor discontinuation in cystic fibrosis patients homozygous for the F508del CFTR mutation. PLoS ONE, 2018, 13, e0209026.	2.5	8
51	VX-659â€“Tezacaftorâ€“Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. New England Journal of Medicine, 2018, 379, 1599-1611.	27.0	280
52	VX-445â€“Tezacaftorâ€“Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. New England Journal of Medicine, 2018, 379, 1612-1620.	27.0	509
53	Pregnancy among cystic fibrosis women in the era of CFTR modulators. Journal of Cystic Fibrosis, 2017, 16, 687-694.	0.7	53
54	Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR. Journal of Cystic Fibrosis, 2017, 16, 371-379.	0.7	46

#	Article	IF	Citations
55	Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis. Journal of Cystic Fibrosis, 2017, 16, 358-366.	0.7	49
56	Tezacaftorâ€“Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del. New England Journal of Medicine, 2017, 377, 2013-2023.	27.0	625
57	Glucose >200â€‰mg/dL during Continuous Glucose Monitoring Identifies Adult Patients at Risk for Development of Cystic Fibrosis Related Diabetes. Journal of Diabetes Research, 2016, 2016, 1-8.	2.3	23
58	Extremes of Interferon-Stimulated Gene Expression Associate with Worse Outcomes in the Acute Respiratory Distress Syndrome. PLoS ONE, 2016, 11, e0162490.	2.5	24
59	SINUSITIS, BRONCHIECTASIS, AND FLATUS IN A SUMATRAN ORANGUTAN (PONGO ABELII): COULD THIS BE CYSTIC FIBROSIS?. Journal of Zoo and Wildlife Medicine, 2016, 47, 347-350.	0.6	4
60	Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United States. Journal of Cystic Fibrosis, 2016, 15, 116-122.	0.7	45
61	Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects. Therapeutic Advances in Respiratory Disease, 2015, 9, 313-326.	2.6	60
62	EnhancedIn VitroFormation and Antibiotic Resistance of Nonattached Pseudomonas aeruginosa Aggregates through Incorporation of Neutrophil Products. Antimicrobial Agents and Chemotherapy, 2014, 58, 6851-6860.	3.2	39
63	Potential of anti-inflammatory treatment for cystic fibrosis lung disease. Journal of Inflammation Research, 2010, 3, 61.	3.5	11